2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2281

An Analysis Of Highly Discordant Erythrocyte Sedimentation and C Reactive Protein Levels In Rheumatoid Arthritis
Abstract Number: 2264

An Assay Panel Combining Anticitrullinated Peptide Autoantibodies and Rheumatoid Factor Isotypes Has High Yield In The Diagnosis Of Rheumatoid Arthritis
Abstract Number: 2525

An Assay Panel Combining Cell Bound Complement Activation Products With Autoantibodies To Extractable Nuclear Antigens and Mutated Citrullinated Vimentin Helps With The Differential Diagnosis Of Systemic Lupus Erythematosus
Abstract Number: 1188

An Assessment Of The Response Of Chronic, Occult, Synovial-Based Inflammation Of Gout To Serum Urate Lowering Therapy
Abstract Number: 2572

An Atypical Cyclin-Dependent Kinase Mediates Fibrosis and Is a Novel Target In Scleroderma
Abstract Number: 2526

An Autoantibody Profile for The Diagnosis Of Systemic Lupus Erythematosus Using the IMMUNARRAY iCHIP™
Abstract Number: 2064

An Autoimmune Myositis-Overlap Syndrome Associated With Autoantibodies To Nuclear Pore Complexes ‒ Description and Long-Term Follow-Up Of The Anti-Nup Syndrome
Abstract Number: 1452

An Early Economic Evaluation Of Personalized Treatment With Rituximab By Prediction Of Effectiveness Using The Interferon Type I Signature In Rheumatoid Arthritis
Abstract Number: 2843

An Education Needs Assessment: Findings From Surveys Of Patients and Caregivers
Abstract Number: 1203

An Escalating Dose Of Anakinra In Patients With Autoinflammatory Disease Is a Safe and Reasonable Therapeutic Option
Abstract Number: 541

An Essential Role For Caspase-1 In The Induction Of Murine Lupus and Its Associated Vascular Damage
Abstract Number: 230

An Examination Of Shoulder Pain Using Magnetic Resonance Imaging In Older People
Abstract Number: 1068

An In-Depth Analysis Of The Prevalence and Socio-Demographic Factors Associated With Lupus Nephritis In Major Industrialized Countries
Abstract Number: 463

An Indirect Comparisons Analysis Between Biologic Disease Modifiers in The Treatment Of Rheumatoid Arthritis To Evaluate For Efficacy and Safety
Abstract Number: 2703

An Intronic CR2 Polymorphism Associated With Systemic Lupus Erythematosus Alters CTCF Binding and CR1 Expression

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].